Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support
IntroductionNo clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated partial thromboplastin time (aPTT) strategies for UFH monitoring during VA-ECLS.MethodsThis is a single-center, retrospective review of VA-ECLS patients who received UFH in the cardiothoracic intensive care unit between July 2019 and November 2023. Standard protocol for UFH titration was aPTT goal of 45-60 sec (<i>n</i> = 52) before September 2021, then transitioned to FXa goal of 0.1-0.2 U/mL (<i>n</i> = 50) thereafter. Inverse probability of treatment weighting was used to balance baseline differences between cohorts.ResultsIn adjusted analyses, 89.3% of FXa patients and 76.0% of aPTT patients achieved goal range for their respective assay. Total UFH duration (4.0 vs 4.0 days, <i>p</i> = .239) and maximum weight-adjusted UFH dose (9.3 vs 9.4 U/hr/kg, <i>p</i> = .823) remained comparable between adjusted FXa and aPTT cohorts. Moreover, in-hospital mortality (50.3% vs 33.9%, <i>p</i> = .133), major bleeding events (20.6% vs 11.2%, <i>p</i> = .292), and thromboembolic events (30.1% vs 30.1%, <i>p</i> = .998) were not significantly different. Extracorporeal circuit thrombosis and cannula site bleeding were the most frequent events in both groups. Multivariate logistic regression found the FXa strategy was not a significant risk factor for the composite outcome of major bleeding or thromboembolism (OR [95% CI]: 1.539 [0.575, 4.116], <i>p</i> = .393).ConclusionsIn adult VA-ECLS patients at our institution, bleeding and thromboembolic complications occurred at a similar rate regardless of which UFH monitoring strategy was utilized. Further studies in larger and more institutionally diverse cohorts are warranted.
Authors
- J. Fried (ORCID: https://orcid.org/0000-0001-6146-2637)
- Yuji Kaku (ORCID: https://orcid.org/0000-0002-1366-1129)
- Koji Takeda (ORCID: https://orcid.org/0000-0001-8263-1911)
- Christine Yang (ORCID: https://orcid.org/0000-0003-2945-4586)
- Paul Kurlansky (ORCID: https://orcid.org/0000-0003-2681-9885)
- Jonathan Hastie
- Iris Feng (ORCID: https://orcid.org/0000-0002-6494-126X)
- Tanner R. Powley
- Lauren D. Sutherland
Institutions
- Columbia University Irving Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- Perfusion
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1177/02676591241309500
- Citations
- 2
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.37